Do not discontinue semaglutide without consulting your healthcare provider, as stopping may affect your diabetes control or weight management goals
Excess fat serves as the primary modifiable risk factor for both the onset and progression of T2DM, underscoring its central role in the pathophysiology of the disease
Beyond glycemic control, these medications initially slow gastric emptying, though this effect may diminish over time with long-acting formulations
However, evidence on the cardiovascular benefits of tirzepatide is only emerging and no randomized study has directly compared it to semaglutide 16,17
Instead of activating only GLP-1 receptors, tirzepatide acts as a dual GLP-1 and GIP receptor agonist
Are You a Semaglutide Candidate